- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04265729
Neocate In Infants and Children With Complex Conditions (NICC)
An Open-label, Explorative, Post Launch Study of Neocate Amino Acid-based Feeds to Evaluate Nutritional Status and Gastrointestinal Tolerance in Infants and Children With Complex Conditions
Infants and young children up to 10 years of age with a complex condition involving the gastrointestinal tract are at risk of poor nutritional status, including faltering growth. Due to the complex condition, standard nutrition is often not tolerated and causes gastrointestinal symptoms.
Formulas in which protein is replaced by its smallest elements, amino acids are easier for the body to digest and absorb. These formulas might be tolerated better and reduce gastrointestinal symptoms in infants and young children with complex conditions.
The objectives of the present, exploratory study are to gain clinical evidence related to the nutritional status and gastrointestinal tolerance in infants and young children with complex conditions receiving Neocate as their primary source of nutrition. Additional objectives are to describe the nutritional and pharmacological management of these infants and young children. Study duration for each participant will be 52 weeks at maximum.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Munich, Allemagne
- Dr. von Haunersches LKinderspital
-
-
-
-
-
London, Royaume-Uni
- Great Ormond Street Hospital
-
-
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30342
- GI Care for Kids
-
-
South Carolina
-
Greenville, South Carolina, États-Unis, 29615
- Prisma Health - Upstate
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Infants and young children aged from 0 up to and including 10 years of age.
- Severe impairment of at least 1 organ system
- Impairment of the gastrointestinal tract, i.e. gastrointestinal disease, congenital abnormality, surgical resection, or gastrointestinal dysfunction (including symptoms of gastrointestinal dysmotility or malabsorption).
- Receiving at least 75% of their energy intake from Neocate (Neocate Infant or Junior powdered (marketed) product) at the time of study entry (V1).
- Expected to receive at least 75% of their energy intake from the study product for at least 4 weeks from study entry (V1).
- Written informed consent provided by parents/guardians and assent by the child, if applicable, according to local law.
Exclusion Criteria:
- Infants born with a gestational age <37 weeks that are <40 weeks corrected age at the time of study entry (V1).
- Infants or children with endoscopically confirmed eosinophilic oesophagitis and prescribed an amino acid-based formula only for the management of the eosinophilic oesophagitis.
- Infants or children with a medical diagnosis that includes only (suspected) cow's milk allergy and/or multiple food allergy.
- Infants or children with renal dysfunction, e.g. acute or chronic kidney failure or kidney cancer.
- Infants or children with thyroid disorder or parathyroid disorder.
- Expected to receive parenteral nutrition during intervention from study entry (V1).
- Participation in any other studies involving investigational or marketed products concomitantly or within 1 month prior to study entry (V1).
- Investigator's uncertainty about the willingness or ability of the parents/guardians to comply with the protocol requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: single test product arm
use of Neocate Infant and Junior marketed products (product type depending on subject's age and condition)
|
use of Neocate Infant and Junior marketed products
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Exploratory: Weight
Délai: 0 weeks
|
Weight [in g/kg]
|
0 weeks
|
|
Exploratory: Weight
Délai: 4 weeks
|
Weight [in g/kg]
|
4 weeks
|
|
Exploratory: Weight
Délai: 16 weeks
|
Weight [in g/kg]
|
16 weeks
|
|
Exploratory: Weight
Délai: 52 weeks
|
Weight [in g/kg]
|
52 weeks
|
|
Exploratory: Length
Délai: 0 weeks
|
Length/height [in cm]
|
0 weeks
|
|
Exploratory: Length
Délai: 4 weeks
|
Length/height [in cm]
|
4 weeks
|
|
Exploratory: Length
Délai: 16 weeks
|
Length/height [in cm]
|
16 weeks
|
|
Exploratory: Length
Délai: 52 weeks
|
Length/height [in cm]
|
52 weeks
|
|
Exploratory: head circumference
Délai: 0 weeks
|
head circumference (for children <2 years of age) [in cm]
|
0 weeks
|
|
Exploratory: head circumference
Délai: 4 weeks
|
head circumference (for children <2 years of age) [in cm]
|
4 weeks
|
|
Exploratory: head circumference
Délai: 16 weeks
|
head circumference (for children <2 years of age) [in cm]
|
16 weeks
|
|
Exploratory: head circumference
Délai: 52 weeks
|
head circumference (for children <2 years of age) [in cm]
|
52 weeks
|
|
Exploratory: Biochemical markers of nutritional status
Délai: 0 weeks
|
Macronutrient, micronutrient and mineral levels in blood [in a.o.
mmol/L]
|
0 weeks
|
|
Exploratory: Biochemical markers of nutritional status
Délai: 4 weeks
|
Macronutrient, micronutrient and mineral levels in blood [in a.o.
mmol/L]
|
4 weeks
|
|
Exploratory: Biochemical markers of nutritional status
Délai: 16 weeks
|
Macronutrient, micronutrient and mineral levels in blood [in a.o.
mmol/L]
|
16 weeks
|
|
Exploratory: Biochemical markers of nutritional status
Délai: 52 weeks
|
Macronutrient, micronutrient and mineral levels in blood [in a.o.
mmol/L]
|
52 weeks
|
|
Exploratory: Gastrointestinal tolerance
Délai: 0 weeks
|
GastrointestinaI symptoms [none/mild/moderate/severe]
|
0 weeks
|
|
Exploratory: Gastrointestinal tolerance
Délai: 4 weeks
|
GastrointestinaI symptoms [none/mild/moderate/severe]
|
4 weeks
|
|
Exploratory: Gastrointestinal tolerance
Délai: 16 weeks
|
GastrointestinaI symptoms [none/mild/moderate/severe]
|
16 weeks
|
|
Exploratory: Gastrointestinal tolerance
Délai: 52 weeks
|
GastrointestinaI symptoms [none/mild/moderate/severe]
|
52 weeks
|
|
Exploratory: Stool frequency
Délai: 0 weeks
|
number of stools per day
|
0 weeks
|
|
Exploratory: Stool frequency
Délai: 4 weeks
|
number of stools per day
|
4 weeks
|
|
Exploratory: Stool frequency
Délai: 16 weeks
|
number of stools per day
|
16 weeks
|
|
Exploratory: Stool frequency
Délai: 52 weeks
|
number of stools per day
|
52 weeks
|
|
Exploratory: Stool consistency
Délai: 0 weeks
|
parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery
|
0 weeks
|
|
Exploratory: Stool consistency
Délai: 4 weeks
|
parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery
|
4 weeks
|
|
Exploratory: Stool consistency
Délai: 16 weeks
|
parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery
|
16 weeks
|
|
Exploratory: Stool consistency
Délai: 52 weeks
|
parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery
|
52 weeks
|
|
Exploratory: Nutrient intake
Délai: 0 weeks
|
calculated energy, protein and micronutrient levels from parent diary [in a.o.
mg/d]
|
0 weeks
|
|
Exploratory: Nutrient intake
Délai: 4 weeks
|
calculated energy, protein and micronutrient levels from parent diary [in a.o.
mg/d]
|
4 weeks
|
|
Exploratory: Nutrient intake
Délai: 16 weeks
|
calculated energy, protein and micronutrient levels from parent diary [in a.o.
mg/d]
|
16 weeks
|
|
Exploratory: Nutrient intake
Délai: 52 weeks
|
calculated energy, protein and micronutrient levels from parent diary [in a.o.
mg/d]
|
52 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MPR18TA23134
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .